About GondolaBio GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. GondolaBio is an independent sister company to BridgeBio, originally carved out in 2024 after securing $300M in private financing from external investors. GondolaBio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.
Neurofibromatosis Type 1 (NF1), a genetic condition where tumors grow on the nerves and skin, is the focus of a pre-clinical stage program in GondolaBio’s portfolio. NF1 affects multiple organ systems, with a wide range of manifestations ranging from neurofibromas (benign nerve sheath tumors) that carry the risk of malignant transformation, to learning difficulties and bone abnormalities. Despite having two FDA-approved MEK inhibitors for NF1 patients, there is still a huge unmet need in providing safer and more efficacious treatment options to the NF1 patients, and GondolaBio strives to address this gap.
To learn more, visit us at gondolabio.com Who You Are You are a strategic and execution-minded clinical operations leader who thrives in a fast-paced, collaborative environment-and you're at your best when the path isn't fully defined. You bring a strong track record of leading global clinical trials, especially phase 2, and you know how to move quickly without compromising quality. You take ownership of outcomes, not just tasks.
You're a self-starter who can independently identify what needs to happen, build an actionable plan, and drive delivery through internal teams and external partners. You communicate crisply, escalate early with solutions, and stay calm and effective when timelines are tight or priorities shift. You are comfortable working quickly on a lean, focused team, willing to be hands on and build a right-sized team if needed.
Job details are sourced from the employer's original posting.
Open job postingAbout the company
This company is involved in clinical pharmacology and early clinical development, focusing on early clinical sciences and development strategy from first-in-human through Phase 2. They also lead quantitative sciences including data analytics, pharmacometrics, biostatistics, and data management to inform dose selection and program development.